Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 84, Issue 3-4, 2011, Pages 79-83

  Reddy, R ^a,c,d   Fleet Michaliszyn, S ^b   Condray, R ^c,d   Yao, J K ^c,d   Keshavan, M S ^e  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

Eicosapentaenoic acid; Executive function; Omega 3 fatty acid; Schizophrenia; WCST

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; ICOSAPENTAENOIC ACID ETHYL ESTER;

ADD ON THERAPY; ADULT; ANALYTICAL ERROR; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; OUTCOME ASSESSMENT; PERSEVERATION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SUPPLEMENTATION; TREATMENT DURATION; WISCONSIN CARD SORTING TEST;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 79151469855     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2010.12.001     Document Type: Article

References (54)

1. Heinrichs R.W. The primacy of cognition in schizophrenia. Am. Psychol. 2005, 60:229-242.
2. Nuechterlein K.H., Dawson M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 1984, 10:160-203.
3. Goldman-Rakic P.S. Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1994, 6:348-357.
4. Barch D.M., Berenbaum H. Language production and thought disorder in schizophrenia. J. Abnorm. Psychol. 1996, 105:81-88.
5. Condray R., van Kammen D.P., Steinhauer S.R., Kasparek A., Yao J.K. Language comprehension in schizophrenia: trait or state indicator?. Biol. Psychiatry 1995, 38:287-296.
6. Lencz T., Smith C.W., McLaughlin D., Auther A., Nakayama E., Hovey L., Cornblatt B.A. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatry 2006, 59:863-871.
7. Bowie C.R., Harvey P.D. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 2005, 28:613-633. 626.
8. Wilk C.M., Gold J.M., McMahon R.P., Humber K., Iannone V.N., Buchanan R.W. No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology 2005, 19:778-786.
9. Rosenheck R., Leslie D., Keefe R., McEvoy J., Swartz M., Perkins D., Stroup S., Hsiao J.K., Lieberman J. Barriers to employment for people with schizophrenia. Am. J. Psychiatry 2006, 163:411-417.
10. Hofer A., Baumgartner S., Bodner T., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., Fleischhacker W.W. Patient outcomes in schizophrenia II: the impact of cognition. Eur. Psychiatry 2005, 20:395-402.
11. Magliano L., Fiorillo A., Malangone C., De Rosa C., Maj M. Social network in long-term diseases: a comparative study in relatives of persons with schizophrenia and physical illnesses versus a sample from the general population. Soc. Sci. Med. 2006, 62:1392-1402.
12. Velligan D.I., Mahurin R.K., Diamond P.L., Hazleton B.C., Eckert S.L., Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 1997, 25:21-31.
13. Prouteau A., Verdoux H., Briand C., Lesage A., Lalonde P., Nicole L., Reinharz D., Stip E. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr. Res. 2005, 77:343-353.
14. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
15. McGurk S.R., Coleman T., Harvey P.D., Reichenberg A., White L., Friedman J., Parrella M., Davis K.L. Working memory performance in poor outcome schizophrenia: relationship to age and executive functioning. J. Clin. Exp. Neuropsychol. 2004, 26:153-160.
16. Reed R.A., Harrow M., Herbener E.S., Martin E.M. Executive function in schizophrenia: is it linked to psychosis and poor life functioning?. J. Nerv. Ment. Dis. 2002, 190:725-732.
17. Harvey P.D., McClure M.M. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs 2006, 66:1465-1473.
18. Peuskens J., Demily C., Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin. Ther. 2005, 27(Suppl A):S25-S37.
19. Gray J.A., Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 2007, 33:1100-1119.
20. McNamara R.K. The emerging role of omega-3 fatty acids in psychiatry. Prostaglandins Leukotrienes Essent. Fatty Acids 2006, 75:223-225.
21. Heinrichs S.C. Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function. Mol. Nutr. Food Res. 2010, 54:447-456.
22. Yehuda S., Rabinovitz S., Mostofsky D.I. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J. Neurosci. Res. 1999, 56:565-570.
23. Yao J.K., Reddy R.D. Membrane pathology in schizophrenia: implication for arachidonic acid signaling. Sci.World J. 2002, 2:1922-1936.
24. Sethom M.M., Fares S., Bouaziz N., Melki W., Jemaa R., Feki M., Hechmi Z., Kaabachi N. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukotrienes Essent. Fatty Acids 2010.
25. Yao J.K., van Kammen D.P. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr. Res. 1994, 11:209-216.
26. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004, 30:901-911.
27. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000, 42:7-17.
28. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 1991, 30:795-805.
29. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr. Res. 2007, 91:37-50.
30. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukotrienes Essent. Fatty Acids 2003, 69:393-399.
31. Joy C.B., Mumby-Croft R., Joy L.A. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst. Rev. 2006, 3:CD001257.
32. Peet M., Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002, 36:7-18.
33. Randolph C., Tierney M.C., Mohr E., Chase T.N. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 1998, 20:310-319.
34. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
35. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33:766-771.
36. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 1994, 13:217-226.
37. Emsley R., Niehaus D.J., Oosthuizen P.P., Koen L., Ascott-Evans B., Chiliza B., van Rensburg S.J., Smit R.M. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res. 2008, 161:284-291.
38. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158:2071-2074.
39. Basso M.R., Bornstein R.A., Lang J.M. Practice effects on commonly used measures of executive function across twelve months. Clin. Neuropsychol. 1999, 13:283-292.
40. Basso M.R., Lowery N., Ghormley C., Bornstein R.A. Practice effects on the Wisconsin card sorting test-64 card version across 12 months. Clin. Neuropsychol. 2001, 15:471-478.
41. McGrath J., Scheldt S., Welham J., Clair A. Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases. Schizophr. Res. 1997, 26:127-137.
42. McCaffrey R.J., Ortega A., Haase R.F. Effects of repeated neuropsychological assessments. Arch. Clin. Neuropsychol. 1993, 8:519-524.
43. Goldberg T.E., Keefe R.S., Goldman R.S., Robinson D.G., Harvey P.D. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010, 35:1053-1062.
44. Hill S.K., Schuepbach D., Herbener E.S., Keshavan M.S., Sweeney J.A. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr. Res. 2004, 68:49-63.
45. Gold J.M., Rehkemper G., Binks S.W., Carpenter C.J., Fleming K., Goldberg T.E., Weinberger D.R. Learning and forgetting in schizophrenia. J. Abnorm. Psychol. 2000, 109:534-538.
46. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64:1115-1122.
47. Whalley L.J., Fox H.C., Wahle K.W., Starr J.M., Deary I.J. Cognitive aging, childhood intelligence, and the use of food supplements: possible involvement of n-3 fatty acids. Am. J. Clin. Nutr. 2004, 80:1650-1657.
48. Berger G.E., Wood S.J., Pantelis C., Velakoulis D., Wellard R.M., McGorry P.D. Implications of lipid biology for the pathogenesis of schizophrenia. Aust. N. Z. J. Psychiatry 2002, 36:355-366.
49. Menesi D., Kitajka K., Molnar E., Kis Z., Belleger J., Narce M., Kang J.X., Puskas L.G., Das U.N. Gene and protein expression profiling of the fat-1 mouse brain. Prostaglandins Leukotrienes Essent. Fatty Acids 2009, 80:33-42.
50. Berger G.E., Wood S.J., Wellard R.M., Proffitt T.M., McConchie M., Amminger G.P., Jackson G.D., Velakoulis D., Pantelis C., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2008, 33:2467-2473.
51. Frangou S., Lewis M., Wollard J., Simmons A. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J. Psychopharmacol. 2007, 21:435-439.
52. Murck H., Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res. Bull. 2007, 72:159-164.
53. Su H.M. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J. Nutr. Biochem. 2010, 21:364-373.
54. Emsley R., Oosthuizen P., van Rensburg S.J. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 2003, 17:1081-1091.